AbbVie is buying immunology biotech Apogee Therapeutics in a $10.9 billion deal, according to Endpoints News, which reports it is the drugmaker's largest acquisition since it bought Allergan.
The prize is Apogee's portfolio of "long-acting" drug candidates aimed at immunology and inflammation (I&I) diseases. The lead asset is zumilokibart, a drug that targets IL-13, a protein involved in inflammatory conditions. Endpoints reports the drug is slated to enter Phase 3 trials for eczema later this year.
The word "long-acting" is the strategic heart of the deal. Many existing immunology treatments require frequent injections; a drug engineered to last longer in the body could mean fewer doses for patients, a meaningful competitive edge in a crowded market.
For AbbVie, the logic is straightforward. The company built much of its modern business on Humira, a blockbuster immunology drug that has lost patent protection and faces cheaper competition. Replenishing that franchise with next-generation candidates is an existential priority, and buying Apogee is a direct move to do exactly that.
It is worth noting the deal is built around candidates still in development rather than approved, revenue-generating products. Zumilokibart has yet to begin its pivotal Phase 3 testing, so the $10.9 billion reflects AbbVie's bet on future trial results, not proven sales.
Why it matters: the acquisition shows how big pharma is paying premium prices to acquire promising biotech pipelines as it races to replace aging blockbuster drugs before their revenue runs dry.